Kornimate/medical-research-clean huggingface dataset:
acute exposure to high altitude on blood and tissue oxygenation (abga, nirs)

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to high altitude (2500m above sea level) on blood and tissue oxygenation (abga, nirs).

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, 6mwt, pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested in low altitude (zurich, 470m) and at high altitude (2500m). at rest and under exercise data from abga and nirs will be compared at low altitude and high altitude.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mpap ≥ 25 mmhg along with a pawp ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting pao2 ≤7.3 kpa corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, hape, etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: high altitude arterial blood gas analysis near infrared spectroscopy
a comparison of the ashc and cdsmp

Conditions: Arthritis

Summary: the arthritis-specific arthritis self help course (ashc) and the more generic chronic disease self management program (cdsmp) teach generalizable skills for managing arthritis and other chronic diseases. in some locations it may be more feasible to combine efforts and offer the generic course rather than the arthritis-specific program. however anecdotal evidence has questioned whether people with arthritis obtain as much benefit from the more generic course as they do the arthritis-specific course. the primary purpose of this research study is to compare health outcomes among people with arthritis who participate in either ashc or the cdsmp. the university of illinois project is emphasizing recruiting a balance of uran and rural participants. the results of this research will be used to guide arthritis program recommendations on the use of ashc and cdsmp to improve the quality of life for people with arthritis.


Eligibility criteria:
inclusion criteria: adult with self reported arthritis- exclusion criteria: -

Keywords: arthritis self management
primary osteoarthritis lumbar spine: establishing its cause, pathogenesis and treatment.

Conditions: Lumbar Osteoarthritis

Summary: the study was about a root cause of primary osteoarthritis lumbar spine producing disabilities in sitting, climbing and walking etc. in advance stage the person is bereft of his/her personal physical activities. the prevalent treatment is temporary and dis-satisfactory. a new treatment was designed and a trial was conducted on 154 patients (100 in the trial group, 50 in the control group) for a duration of six months.

the study was focused on establishing the cause, pathogenesis and treatment of painful lumbar spine disease (primary osteoarthritis lumbar spine = oa lumbar spine) at present the exact cause and treatment are not known. it was aimed to find out to latter through a hypothesis by designing a treatment and testing it with a clinical trial. this established that the deficient full extension of the spinal joints (intervertebral joints between the adjacent vertebrae from t12 to s1) producing contracture in their capsules in front, was the cause and the correction (contracture correction therapy = cct) was the cure of the disease. the correction was carried out by intermittent and sustained extension of the lumbar spin through three designed body postures.

Eligibility criteria:
inclusion criteria: * age =\>30 and \<=90 years * back/leg pain or both combined, which appears without any apparent cause, exacerbated by exertion and subsides by rest. * presence of limited morning stiffness * no history of infection, inflammation or trauma to rule out secondary oa * disability in sitting, climbing stairs or walking exclusion criteria: * neckache * frozen shoulder * central obesity * acute lumbago * x-ray spine with no oa signs

Keywords: osteoarthritis lumbar spine intervertebral joint capsule contracture discectomy ideopathic
evaluation of rc28-e injection in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of rc28-e injection in the treatment of patients with diabetic macular edema.


Eligibility criteria:
inclusion criteria: * sign the consent form, willing and able to comply with clinic visits and study-related procedures; * aged 18 years to 80 years, male or female; * diabetes mellitus(type 1 or 2); * the study eye must followed: 1. retinal thickening secondary to diabetes mellitus (dme) involving the center of the fovea; decrease in vision determined to be primarily the result of dme and not to other causes. 2. bcva score in the study eye of 73 to 24 using the etdrs protocol at an initial testing distance of 4 meters. 3. the central subfield thickness ≥300μm in the center subfield as assessed on oct by the reading center; * if both eyes meet the inclusion criterion, one eye with poor bcva is selected as the study eye; the researchers judged that the fellow eye should not be treated with other anti-vegf drugs recently. exclusion criteria: * the macular edema caused by others instead of diabetes mellitus; * structural damage to the center of the macula in the study eye that is likely to preclude improvement in bcva following the resolution of macular edema including atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant macular ischemia or organized hard exudates; * current iris neovascularization, vitreous hemorrhage, tractional retinal detachment or epiretinal membrane involving the macula in the study eye; * only one functional eye even if that eye is otherwise eligible for the study; * evidence of periocular or intraocular inflammation or infection including infectious blepharitis, keratitis, scleritis, conjunctivitis, endophthalmitis or uveitis at screening assessment in either eye; * previous treatment with anti-angiogenic drugs in either eye or system (ranibizumab, aflibercept, conbercept, etc) within 3 months of the day 0; * history of cardiovascular and cerebrovascular events within 6 months of screening visit: myocardial infarction, unstable angina pectoris, ventricular arrhythmias, new york heart association grade ii + heart failure, stroke, etc.; * uncontrolled clinical disease (such as severe psychiatric, neurological, cardiovascular, respiratory disease or other systemic diseases) and tumors; * those who participated in clinical trials for 3 months or 5 half-lives of the investigational product (the longer the time) before the baseline period; * those who considered unsuitable for enrollment by investigator.
lost children society (lcs), online therapeutic tabletop role-playing game for early-onset schizophrenia patients

Conditions: Schizophrenia

Summary: the lost children society (lcs) is a therapeutic tabletop role-playing game specifically developed for early-onset schizophrenia patient. it is performed online via a secure teleconsultation and videoconference platform. patients are connected from their home, on their personal computer or tablet, equipped with headsets with microphone. this study aims to validate the feasibility of this online therapeutic tabletop role playing game.


Eligibility criteria:
inclusion criteria: * diagnosis of early onset schizophrenia * patient who has the capacity to understand the protocol and to perform evaluations * written informed consent to participate in the study given by the patient or by the parental authority of the minor patient. * patient with social security coverage exclusion criteria: * intelligence quotient\<70 on wechsler adults intelligence scale-iv (for 17+ years) or the wechsler intelligence scale for children v (for 15-16 years). * personal history of head trauma, neurological disorder, genetic disease. * co-morbidities: major depressive episode or post-traumatic stress disorder unresolved or resolved within the last 6 months. * lack of mastery or access to a computer or personal tablet in autonomy * therapeutic history of metacognitive training. * patient under guardianship, curators or legal protection * patient going through a period of exacerbation of positive or negative psychotic signs likely to lead to a full-time hospitalization in a specialized environment within the next 3 months

Keywords: metacognitive training early-onset schizophrenia therapeutic tabletop role playing game psychoeducational program lost children society
respiratory disorders non-invasive monitoring of work of breathing in outpatients

Conditions: Copd; Asthma; Respiratory Effort; Contactless Vital Sign Monitoring

Summary: this study will test the accuracy of an investigational, non-invasive device for measuring heart rate and respiratory rate. the device emits radiowaves that allows it to pick up subtle changes in a person's chest wall, which allows it to calculate the heart rate and respiratory rate. we propose to study whether the device's measurements are accurate and reproducible in patients with chronic obstructive pulmonary disease (copd) or asthma. the device undergoing study has been evaluated in healthy volunteers, but its accuracy in vital sign monitoring in patients with respiratory conditions has not yet been established. this study will serve as the foundation for additional work to assess the device's accuracy in measuring a patient's overall "work of breathing" or respiratory effort. future work will examine the device's accuracy in measuring work of breathing in patients having an exacerbation of their underlying respiratory condition. the primary aim of this study will be to assess the validity of heart rate and respiratory rate measurements in patients with either copd or asthma.


Eligibility criteria:
inclusion criteria: * patient seen at the stanford university hospital chest clinic * patient age 18 or older * patient able to consent * patient with one of the following two medical conditions: chronic obstructive pulmonary - disease or asthma * participant (or accompanying family / caretaker) able to speak english exclusion criteria: * patient does not meet inclusion criteria (under age 18, unable to consent, etc.) * patient is hospitalized * patient is having an acute exacerbation of their respiratory condition * patient is having an acute exacerbation of a comorbid condition * patient has comorbid cardiac disease, including one of the conditions listed below: * arrhythmias (including atrial fibrillation, nsvt, etc.) * congestive heart failure * unstable angina * myocardial infarction within the last 3 months prior to enrollment * uncorrected congenital heart disease * uncorrected severe valvular disease * pulmonary hypertension (moderate or higher grade) * patient has one of the following conditions: * moderate pleural effusion * large pleural effusion * advanced stage lung cancer (stage iii or stage iv disease) * active infectious process, including viral process or pneumonia * interstitial lung disease * pleural disease, including pleural malignancies, trapped lung, etc * active cheyne-stokes respiration * patient has baseline increased work of breathing not due to their underlying respiratory disease (ie. copd or asthma) * ongoing substance abuse (not including cigarette use)
preoperative parenteral thiamine supplementation in patients undergoing heart surgery

Conditions: Heart Failure; Acidosis, Lactic; Thiamine Deficiency

Summary: the objective of this study is to determine whether preoperative parenteral thiamin supplementation does prevent the intra and early postoperative increase of lactate and whether this effect is related to the extent of thiamine deficiency in patients undergoing heart surgery. in addition the prevalence of major thiamin deficiency in patient undergoing heart surgery will be determined.

thiamine (vitamin b1) is a water-soluble vitamin and is involved in several stages of intermediate metabolism which are important for producing energy. severe thiamin deficiency has been associated with severe lactic acidosis and clinical symptoms of life threatening heart failure. to date, no study has evaluated thiamine levels in patients undergoing heart surgery and the prevalence of thiamine deficiency is not known. furthermore it is unknown whether moderately reduced thiamin levels are associated with mild forms of perioperative cardiac failure necessitating prolonged inotropic support. in this prospective double blind randomised controlled trial of the effect of a parenteral infusion of thiamin before induction of anaesthesia we will investigate the effect on perioperative lactate increase as primary outcome and extent and duration of inotropic support after cardiac surgery. in addition the pharmacokinetics of a intravenous infusion of 300 mg of thiamin on erythrocyte thiamin content and the amount of thiamine excreted in the 24 hours via the urine will be determined. baseline thiamin levels in erythrocytes before surgery, as well as nutrition history and body composition will be evaluated as effect modifier.

Eligibility criteria:
inclusion criteria: * age 18 - 100 years * planned heart surgery * signed informed consent exclusion criteria: * pregnancy and lactation * known allergic reaction to the drugs used * mental condition rendering the patient unable to give informed consent * inability or contraindications to perform study procedures

Keywords: thiamine vitamin b1 thiamine deficiency thiamine supplementation cardiac surgery lactic acid
unilateral attachment versus tooth implant supported bridge

Conditions: Edentulous Jaw

Summary: purpose: evaluation of patients' satisfaction, biting force measurement and radiographic evaluation of abutment teeth of tooth implant supported bridge, unilateral attachment and conventional partial denture in mandibular distal extension cases. materials and methods: twenty four patients were selected and divided into three equal groups, each of eight patients: patients of group i patients received a fixed tooth implant supported bridge, patients of group ii patients received a removable unilateral attachment partial denture and group iii patients received a conventional removable partial denture.evaluation included patient satisfaction and biting force measurement radiographic evaluation of terminal abutments.

purpose: evaluation of patients' satisfaction, biting force measurement and radiographic evaluation of abutment teeth of tooth implant supported bridge, unilateral attachment and conventional partial denture in mandibular distal extension cases. materials and methods: twenty four patients were selected according to the following criteria: patients with unilateral mandibular distal extension with last standing second premolar abutment, abutments showed sufficient occluso-gingival height and good periodontal condition. patients were divided into three equal groups, each of eight patients: patients of group i patients received a fixed tooth implant supported bridge, patients of group ii patients received a removable unilateral attachment partial denture and group iii patients received a conventional removable partial denture.evaluation included patient satisfaction using "ohip14" questionnaires and biting force measurement radiographic evaluation of terminal abutments.

Eligibility criteria:
inclusion criteria: * unilateral mandibular distal extension area * the abutments showed sufficient occluso-gingival height of its clinical crown * adequate inter-arch space and no tempro-mandibular joint disorders. * no para-functional habits, * full opposing arch or restored with acceptable fixed restoration * minimal bone height11 mm at the lower second molar area. exclusion criteria: \*insufficent bone height in posterior area of mandible

Keywords: attachment, patient satisfaction radiographic evaluation implant
safety and effectiveness of adding pmpa prodrug to an anti-hiv drug combination to treat hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to add pmpa prodrug (a new anti-hiv drug) to an anti-hiv drug combination taken by patients who have taken anti-hiv drugs in the past. genetic response will be studied.

prior to study entry patients are stratified according to hiv-1 rna level, cd4 cell count, and number of antiretroviral drugs. pmpa prodrug or placebo is added to current antiretroviral regimens, and is administered in one of three dosing regimens. patients randomized to receive placebo are eligible to receive open-label pmpa prodrug for the remainder of the 48-week study period after at least 24 weeks post randomization.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * have an hiv count of 400 - 50,000 copies/ml. * are expected to live for at least 1 year. * have been taking the same anti-hiv drug combination (made up of no more than 3 anti-hiv drugs) for at least 8 weeks prior to study entry. * are at least 18 years old. * agree to use effective methods of birth control during the study. exclusion criteria you will not be eligible for this study if you: * have taken medications for certain infections within 15 days prior to study entry. * have a history of cancer, except kaposi's sarcoma (ks) or skin cancer. * develop a new aids-related condition within 30 days of study entry. * have certain serious medical conditions, including severe nausea, vomiting, or other stomach problems that make you unable to take medications by mouth. * have received a vaccine within 30 days prior to study entry. * have taken certain medications, including those that may affect your kidneys. * abuse alcohol or drugs. * are pregnant.

Keywords: drug therapy, combination prodrugs anti-hiv agents
impact of novel thoracic wall blocks with dexmetomidine on inflammatory markers following breast cancer surgery

Conditions: Inflammatory Markers

Summary: the study will test the hypothesis that inflammatory markers measured at 24 hours after breast cancer surgery will be lower in patients receiving pecs ii and pifb blocks, supplemented with dexmetomidine compared to standard care group.

breast cancer is a devastating disease. surgery is the mainstay of treatment which can lead to ongoing patient difficulties. severe acute pain after surgery is one of major risk factors for developing persistent postsurgical pain. subsequent physiological stress caused by this severe pain may negatively influence the immune response leading to a worse prognosis. regional anesthesia is very effective in management of peri- and postoperative pain. epidural block, paravertebral block and intercostal nerve blocks have been proven over time to be effective in preventing postoperative pain. however, their widespread use has been hampered by technical difficulty and inherent risks. unlike the aforementioned blocks, novel thoracic wall blocks, namely modified pectoralis block (pecs ii) and pecto-intercostal fascial block (pifb) are safe, simple and effective. efforts to prolong and improve analgesia following single shot blocks has led to the introduction of adjuvants into the local anesthetic. dexmetomidine is a superselective alpha 2 agonist with a proven ability to prolong the duration of neuraxial, peripheral nerve and interfascial plane blocks. chronic inflammation is recognized as a risk factor for initiation, progression and further spread of malignant growth. surgical insult leads to inflammatory response which facilitates the development of a metastatic disease. many inflammatory markers were proven to be independent prognostic factors in breast cancer patients. the investigators propose to study the impact of novel thoracic wall blocks with dexmetomidine on simple inflammatory markers obtained from full blood count (nlr, plr, npr, pdw, mpv, rdw) after breast cancer surgery.

Eligibility criteria:
inclusion criteria: * female patients with ductal carcinoma (stage 1 to 3) undergoing primary potentially curative unilateral mastectomy. * older than 18 years * asa i-iii exclusion criteria: * weight \< 50 kg * bmi \> 35 * allergy to local anaesthetic or dexmetomidine * contraindications to nsaids use * local infection over block site * coagulopathy * preexisting chronic pain * pregnancy * autoimmune disease * inability to give informed consent

Keywords: pec ii pifb breast cancer nlr
a pilot study to assess the safety, tolerability, and efficacy of virtual reality for the treatment of abdominal pain in quiescent crohn's disease

Conditions: Crohn's Disease; Abdominal Pain (AP)

Summary: the purpose of this research is to see if patients with crohn's disease (cd) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (vr).

the goal of this research is to see if patients with crohn's disease (cd) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (vr). the use of vr therapy is investigational. you have been asked to take part in this research because you have been identified as an adult with cd with abdominal pain at least weekly despite normal c-reactive protein and fecal calprotectin levels in adult patients, age 18- 70 years old. demographic information will be gathered (age, sex, race, current medication use, co-morbid conditions), as will prior tests and interventions. participants will be asked to participate in the two-week pre-screening evaluation for symptoms through questionnaires. the vr portion of the study will last for 8 weeks. you will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like. you will be called on a weekly basis.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of endoscopically and histologically confirmed cd with evidence of c-reactive protein \&lt; 5 mg/dl and fecal calprotectin \&lt; 150microg/g who also report any abdominal pain at least weekly will be included. exclusion criteria: * patients will be excluded from the study if they do not have biopsy-proven cd, have a known seizure disorder, if symptoms are thought to represent an organic disorder, those with visual or hearing impairments, if symptoms represent a known pelvic floor disorder, if the patient is using opioids, has significant ongoing psychological distress (had score \&gt; 11 for either anxiety or depression), or if the patient can not actively participate in the study for any other reason (e.g., inability to understand english as the vr program as an english only).

Keywords: crohn's disease quiescent crohn's disease